Supernus Pharmaceuticals Other Long-Term Assets 2011-2024 | SUPN
Supernus Pharmaceuticals other long-term assets from 2011 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Supernus Pharmaceuticals Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$38 |
| 2022 |
$40 |
| 2021 |
$49 |
| 2020 |
$43 |
| 2019 |
$22 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$0 |
| 2013 |
$1 |
| 2012 |
$0 |
| 2011 |
$0 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$36 |
| 2024-03-31 |
$38 |
| 2023-12-31 |
$38 |
| 2023-09-30 |
$39 |
| 2023-06-30 |
$38 |
| 2023-03-31 |
$40 |
| 2022-12-31 |
$40 |
| 2022-09-30 |
$41 |
| 2022-06-30 |
$47 |
| 2022-03-31 |
$49 |
| 2021-12-31 |
$49 |
| 2021-09-30 |
$40 |
| 2021-06-30 |
$41 |
| 2021-03-31 |
$30 |
| 2020-12-31 |
$43 |
| 2020-09-30 |
$18 |
| 2020-06-30 |
$17 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$22 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$0 |
| 2014-06-30 |
$0 |
| 2014-03-31 |
$0 |
| 2013-12-31 |
$1 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$0 |
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.771B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
